{"id":"NCT04706793","sponsor":"Pfizer","briefTitle":"Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)","officialTitle":"A Phase 3, Double-Blind, Placebo-Controlled, 40-Week Extension Study to Assess the Efficacy and Safety of Etrasimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-25","primaryCompletion":"2022-08-03","completion":"2022-08-03","firstPosted":"2021-01-13","resultsPosted":"2023-10-16","lastUpdate":"2023-10-16"},"enrollment":42,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Etrasimod","otherNames":["APD334"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Etrasimod 2 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment in adult Japanese participants with moderately to severely active ulcerative colitis (UC). This study is an extension of study APD334-302 (NCT03996369). Participants will continue with the same blinded treatment assigned in Study APD334-302 for a total treatment duration of 52 weeks (12 weeks in Study APD334-302 plus 40 weeks in Study APD334-308).","primaryOutcome":{"measure":"Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308","timeFrame":"Week 40 of APD334-308","effectByArm":[{"arm":"Placebo Comparator: Placebo","deltaMin":7.1,"sd":null},{"arm":"Experimental: Etrasimod 2 mg","deltaMin":25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":38,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=APD334-308"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":14},"commonTop":["Headache","Pyrexia","Colitis ulcerative","Malaise","Vaccination site pain"]}}